Published in Healthcare Mergers, Acquisitions and Ventures Week, March 24th, 2007
The company's New Drug Application (NDA) for LCP-FenoChol will therefore not be subject to a so-called 30-month stay under the Hatch-Waxman Act.
Assuming regulatory approval, the company expects LCP-FenoChol to be ready for market launch in the United States in early 2008.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Healthcare Mergers, Acquisitions and Ventures Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.